Although MMP-9 inhibitors have great anti-cancer therapeutic potential in clinical trials, their efficiency in advanced cancer patients remains unsatisfactory partly due to the lack of understanding the complexities of MMP-9 involvement in cancer progression and due to the lack of inhibitor specificity [34]. This evidence concerns the gene MMP9 and cancer.